Abbott Laboratories
ABT · NYSE
Company research
Abbott Laboratories (NYSE: ABT) is a global diversified healthcare company headquartered in Abbott Park, Illinois, founded in 1888, with approximately 114,000 employees operating in more than 160 countries. The company develops, manufactures, and sells a broad portfolio of healthcare products across four core business segments: Medical Devices (including cardiovascular devices, continuous glucose monitoring systems such as FreeStyle Libre, and neuromodulation products), Diagnostics (comprising laboratory systems, molecular diagnostics, and rapid point-of-care tests), Nutritional Products (including well-known brands such as Similac and Ensure), and Established Pharmaceuticals (branded generic medicines primarily sold in emerging markets). With approximately $44.33 billion in annual revenue and a market capitalization of approximately $165 billion, Abbott derives roughly 60% of its sales from outside the United States, reflecting its strong international presence. Under the leadership of Chairman and CEO Robert B. Ford, Abbott continues to invest in research and development to introduce breakthrough technologies that improve patient outcomes across the full spectrum of healthcare needs.
Research reports
Sure Dividend · January 22, 2026Abbott Laboratories (ABT)
This dividend-focused fundamental report rates ABT as a buy, with a 5‑year annual expected total return of 11.4%, a 5‑year price target of 175, and projected EPS growth of about 7% per year from a 2026 EPS base of 5.68. It highlights Abbott’s diversified med‑tech and diagnostics portfolio, very resilient earnings through past recessions, a 54‑year dividend growth streak, a safe sub‑50% payout ratio, and room for valuation multiple expansion from roughly 19.5× to a 22× target, while noting near‑term risks mainly around valuation and normalizing post‑COVID growth.
ChartMill · December 21, 2025ABBOTT LABORATORIES (ABT) Stock Fundamental AnalysisThis HTML fundamental analysis assigns ABT an overall fundamental score of 7/10, with strong profitability (8/10), solid financial health (8/10), and an excellent dividend profile, while describing the shares as fairly valued (valuation 4/10) given current multiples. The report’s thesis is that Abbott’s combination of quality earnings, reasonable valuation, decent growth, and strong dividend metrics makes it suitable for dividend and quality investing strategies, though it stops short of a formal buy/sell rating and emphasizes balanced upside versus valuation risk.
Balfour Capital Group · December 12, 2025Abbott Laboratories (ABT) ResearchThis institutional-style profile, published 12.12.25, reviews Abbott’s diversified operations across medical devices, diagnostics, nutrition, and established pharmaceuticals, emphasizing Q3 2025 revenue of 10.3 billion (+7% YoY) and segment growth led by medical devices (+12% YoY) and emerging‑market generics. It frames the outlook as constructive, citing robust CGM demand (Libre 3/4), improving margins from mix and supply‑chain efficiencies, and broad buy/overweight recommendations and a 12‑month consensus target range of 110–145 (average 122–130), while noting macro, competitive, and regulatory risks typical for large‑cap healthcare.
Koala Gains · October 31, 2025Abbott Laboratories (ABT) Stock Analysis & Key MetricsThis long-form equity analysis (updated October 31, 2025) applies a Buffett/Munger‑style intrinsic value framework, concluding that Abbott is a global, diversified healthcare “powerhouse” with roughly 7% revenue growth, 19% operating margins, and strong cash generation exceeding about 6.3 billion annually. The thesis is that ABT’s moat is strongest in medical devices and diagnostics (high switching costs, large installed base, regulatory barriers), but somewhat weaker in nutrition and emerging‑market pharmaceuticals, so with the stock viewed as fairly valued it is positioned as a stable core holding for long‑term, dividend‑growth investors rather than an aggressive upside opportunity.